Seth P Lerner
Overview
Explore the profile of Seth P Lerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
9360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apolo A, Baumann B, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251319185.
PMID: 40034245
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led...
2.
Carrero Longlax S, Koster K, Kamat A, Lozano M, Lerner S, Hannigan R, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofaf007.
PMID: 39872813
Background: The BCG vaccine induces trained immunity, an epigenetic-mediated increase in innate immune responsiveness. Therefore, this clinical trial evaluated if BCG-induced trained immunity could decrease coronavirus disease 2019 (COVID-19)-related frequency...
3.
Scilipoti P, Moschini M, Li R, Lerner S, Black P, Necchi A, et al.
Eur Urol
. 2024 Dec;
PMID: 39730299
Background And Objective: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of...
4.
Lerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, et al.
N Engl J Med
. 2024 Nov;
391(13):1206-1216.
PMID: 39589370
Background: Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is unclear. Methods:...
5.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39521639
Although obesity has been associated with better overall survival (OS) among patients with metastatic castration-resistant prostate cancer, its association with OS has not been extensively explored in metastatic hormone-sensitive prostate...
6.
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400287.
PMID: 39499893
Purpose: Alterations in DNA damage response (DDR) genes, including , have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314...
7.
Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, et al.
Bladder Cancer
. 2024 Nov;
10(3):199-213.
PMID: 39493817
Background: Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therapeutics in different...
8.
Barata P, Tangen C, Plets M, Thompson Jr I, Narayan V, George D, et al.
J Clin Oncol
. 2024 Sep;
42(33):3911-3916.
PMID: 39255440
JCO Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057),...
9.
Kami Reddy K, Piyarathna D, Park J, Putluri V, Amara C, Kamal A, et al.
JCI Insight
. 2024 Sep;
9(17).
PMID: 39253977
Bladder cancer (BLCA) mortality is higher in African American (AA) patients compared with European American (EA) patients, but the molecular mechanism underlying race-specific differences are unknown. To address this gap,...
10.
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, et al.
Eur Urol
. 2024 Aug;
86(6):516-527.
PMID: 39183090
Background And Objective: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations...